Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BIMI International Medical Inc. (NFEC)
|
Add to portfolio |
|
|
|
| Price: |
$0.51
| | Metrics |
| OS: |
4.38
|
M
| |
|
|
| Market cap: |
$2.26
|
M
| |
|
|
|
Net debt:
|
$88.2
|
k
| |
|
|
|
EV:
|
$2.35
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($8.5)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 27.1 | 12.8 | 1.0 | 0.2 | 8.5 | 6.0 | 6.7 | 10.0 |
| Revenue growth | 110.8% | 1202.8% | 363.8% | -97.5% | 40.8% | -10.0% | -32.7% | 75.9% |
| Cost of goods sold | 22.5 | 10.4 | 1.0 | 0.2 | 7.6 | 5.9 | 5.5 | 8.5 |
| Gross profit | 4.6 | 2.4 | 0.0 | 0.0 | 0.9 | 0.1 | 1.2 | 1.5 |
| Gross margin | 17.0% | 19.0% | 0.0% | 0.0% | 10.8% | 2.5% | 17.5% | 14.9% |
| Sales and marketing | 3.2 | 0.8 | | | 0.1 | 0.0 | 0.1 | 0.0 |
| Research and development | | | | | | | | |
| General and administrative | 7.5 | 5.5 | 1.0 | 0.2 | 2.0 | 1.6 | 1.7 | 1.8 |
| EBIT | -6.1 | -3.8 | -1.0 | -0.2 | -1.2 | -1.5 | -0.6 | -0.4 |
| EBIT margin | -22.6% | -29.7% | -100.0% | -100.0% | -14.0% | -24.5% | -9.5% | -3.8% |
| Pre-tax income | -34.9 | -3.4 | -1.5 | -0.2 | -1.6 | -1.8 | -1.0 | -0.6 |
| Income taxes | 0.0 | 0.4 | 2.9 | 16.6 | 0.0 | 0.0 | 0.0 | 0.1 |
| Tax rate | | | | | | | 4.0% | |
| Earnings from continuing ops | -35.0 | -3.9 | -1.5 | -16.8 | -1.6 | -1.8 | -1.0 | -0.6 |
| Earnings from discontinued ops | | 1.9 | -2.9 | | | | | |
| Net income | -35.0 | -2.0 | -4.4 | -16.8 | -1.6 | -1.8 | -1.0 | -0.6 |
| Net margin | -129.2% | -15.5% | -450.2% | -7896.5% | -18.5% | -30.1% | -14.4% | -6.2% |
| |
| Diluted EPS | ($6.52) | ($1.83) | ($0.19) | ($2.24) | ($0.22) | ($0.28) | ($0.15) | ($0.11) |
| Shares outstanding (diluted) | 5.4 | 2.1 | 8.2 | 7.5 | 7.1 | 6.6 | 6.3 | 5.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|